Events

Rappel de Absorb Bioresorbable Vascular Scaffold (BVS) System

Selon Department of Health, Therapeutic Goods Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à Australia qui a été fabriqué par Abbott Vascular Division of Abbott Australasia Pty Ltd.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    RC-2016-RN-00987-1
  • Classe de risque de l'événement
    Class II
  • Date de mise en oeuvre de l'événement
    2016-07-29
  • Pays de l'événement
    Australia
  • Source de l'événement
    DHTGA
  • URL de la source de l'événement
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2016-RN-00987-1
  • Notes / Alertes
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notes supplémentaires dans les données
  • Cause
    Abbott vascular is issuing an update to the recall for product correction that was initiated on december 7, 2015 (tga ref: rc-2015-rn-01188-1) for all sizes of absorb bioresorbable vascular scaffold (bvs) system. the purpose is global alignment of absorb indication - increase from 2.0 mm to 2.5 mm in minimum target vessel diameter indicated for implantation of this coronary stent.Abbott vascular plans to align the indications for absorb across all geographies for reference vessel diameter and as such the indication section and target vessel diameter and ranges table of the ifu are being updated. patients who have had absorb scaffolds successfully implanted are not affected by this action.
  • Action
    Abbott Vascular are issuing revised Instructions for Use (IFU), and are advising users to ensure; When Performing Lesion Sizing and Preparation, the treated lesion length should be less than the nominal scaffolding length, with reference vessel diameters = 2.5 mm and = 3.75 mm (previously = 2.0 mm and = 3.8 mm). In small vessels (visually assessed reference vessel diameter = 2.75 mm), on-line QCA or intravascular imaging with intravascular ultrasound or optical coherence tomography is strongly recommended to accurately measure and confirm appropriate vessel sizing. If quantitative imaging determines a vessel size < 2.5 mm, do not implant the Absorb BVS / Absorb GT1 BVS. Under-expansion of the scaffold may result in scaffold movement. Care must be taken to properly size the scaffold to ensure that the scaffold is in full contact with the arterial wall upon deflation of the balloon. All efforts should be made to assure that the scaffold is not under dilated.

Device

Absorb Bioresorbable Vascular Scaffold (BVS) System

Manufacturer

Abbott Vascular Division of Abbott Australasia Pty Ltd
  • Société-mère du fabricant (2017)
    Abbott Laboratories
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DHTGA